Dorking PCN

With 24.9% aged 65+, an older demographic may elevate PCN frailty needs

Dorking PCN cares for 44,841 registered patients across four practices. The population is older than benchmarks: 24.9% are aged 65+ (11,154 patients), compared with 23.4% in Mole Valley, 18.8% in NHS Surrey Heartlands ICB, and 17.9% in England. Children aged 0–17 comprise 17.2% (7,705 patients), below Mole Valley (18.3%), the ICB (20.4%), and England (19.6%). Census data show 93.2% of local residents identify as White (Mole Valley 92.7%, ICB 85.3%, England 81.1%), with a 6.8% ethnic minority share, though Census resident figures do not match registered-patient lists directly.

Average IMD decile is 7.6 with 0.0% of registered patients in Core20 areas

The PCN average IMD decile is 7.6, less deprived than England (5.5) but below Mole Valley (8.2) and NHS Surrey Heartlands Integrated Care Board (7.9). Practice deciles range from 6.7 at Leith Hill Practice to 7.8 at Dorking Medical Practice (Brockwood Medical Practice 7.6, Medwyn Surgery 7.7). Core20 share is 0.0% across all practices (England 21.0%, ICB 0.8%, Mole Valley 0.0%), with an estimated 0 patients. With zero patients in Core20 deciles, health inequality work may need to target inclusion cohorts and clinical risk rather than area deprivation.

PLUS groups and inclusion health

The PCN records 174 learning disability patients (0.4% prevalence vs Mole Valley 0.5%, ICB 0.5%, England 0.6%) and 434 severe mental illness patients (1.0%). The catchment contains 26 care homes with 977 beds, though resident registration is unconfirmed. Recorded learning disability prevalence sits below England, so register validation could help confirm complete health check reach.

Severe mental illness: physical health checks

For 434 severe mental illness patients, annual BMI checks (76.6%) trail England (82.1%), falling 1.9 pp over three years (England +5.1 pp). BP checks (80.8%) also lag England (83.4%), indicating overdue physical health checks to audit.

Clinical focus: hypertension and lipids

Hypertension case-finding and control

Recorded hypertension prevalence is 17.0% (7,706 patients), above Mole Valley (16.3%), the ICB (14.3%) and England (15.2%), ranging from 14.0% at Medwyn Surgery to 19.6% at Brockwood Medical Practice. Three-year register growth of +2.1% trailed England (+5.6%) and the ICB (+5.3%). However, clinical control is strong: 73.7% are treated to target (England 70.3%), with recent checks at 90.5% (England 90.0%). Control reaches 72.0% for patients aged under 80 (England 67.8%) and 82.5% for those aged 80+ (England 81.2%). Crude prevalence is not age-adjusted. While treatment control exceeds national benchmarks, slower register expansion could reflect case-finding variation, testable by clinical audit of screening protocols.

Lipids and statins

Lipid-lowering therapy uptake trails England across high-risk cohorts: 61.6% for QRISK ≥ 20% (England 63.6%), 66.4% in CKD (England 70.3%), and 81.9% for diabetes with secondary CVD (England 84.4%). Lower uptake than national benchmarks across high-risk cohorts suggests an opportunity to audit lipid therapy recall protocols.

For lipid-modifying drugs, the PCN prescribed 73,762 items in 2025, spending £149,737 at £2.03 per item. Unit cost is above England (£1.82) but below Mole Valley (£2.15) and NHS Surrey Heartlands Integrated Care Board (£2.18). The PCN spent £15,490 more than at England's unit cost, and £11,064 less than at the ICB's unit cost.

Clinical focus: respiratory, cancer register and children

Respiratory

Across 3,066 registered asthma patients (prevalence 7.1% vs England 6.6%), 66.8% had an annual review (England 65.7%), leaving about 1,000 without a recorded review (calculated 1,017). Asthma prescribing for ages 5–19 is 956 per 1,000 (England 1,488). Meanwhile, COPD prevalence is 1.7% (781 patients; England 1.9%), but annual reviews at 74.7% lag England (76.4%) and the ICB (77.7%), despite +10.7% three-year growth (England +2.8%). This pattern could indicate recall gaps across both respiratory registers.

Cancer register and children's immunisation

Cancer prevalence is 4.8% (2,169 patients; England 3.8%). In childhood immunisations, 12-month 6-in-1 reaches 95.6%, but 24-month coverage dips to 90.2% (ICB 94.3%) and MMR1 to 86.6% (ICB 91.4%), both below the 95.0% target. By age 5, MMR1 achieves 98.0% while MMR2 is 92.9%, leaving a 5.1 pp dose gap to recover through active recall.

Early cancer diagnosis

Across NHS Surrey Heartlands ICB in 2022, 61.4% of staged cancers (2,955 of 4,810) were diagnosed at stage 1 or 2, exceeding England (55.3%) but 13.6 pp below the 75.0% national ambition for 2028. Known staging was recorded for 67.7% of registered cancers (4,810 of 7,106). Reaching 75.0% requires about 650 additional early diagnoses across the ICB. Early detection was 88.2% for breast cancer but 33.2% for lung. Locally, PCN cervical screening coverage is 72.0% (England 66.8%), though three-year change was -2.5% (England -1.0%). Prioritising screening recall can support earlier diagnosis.

Cancer waits, diagnostics and community services

Cancer waits and diagnostics, Jul 2026 (provisional)

In July 2026, Surrey and Sussex Healthcare NHS Trust met the 28-day faster diagnosis standard at 77.7% (standard 75.0%) and the 31-day combined treatment standard at 96.2% (standard 96.0%). However, 62-day referral to treatment was 70.0% against the 85.0% standard, below Royal Surrey NHS Foundation Trust (84.5%), Epsom and St Helier University Hospitals NHS Trust (86.8%), NHS Surrey and Sussex Integrated Care Board (71.5%), and England (71.2%).

Patient satisfaction exceeds England but phone access varies by 27.3 percentage points

In 2025/26, all four practices achieved 100.0% in QOF clinical points (England 97.1%). However, vaccination achievement varied by 45.8 pp, from 54.2% at Brockwood Medical Practice to 100.0% at Dorking Medical Practice (England 55.2%). High clinical scores may mask uptake disparities, meaning childhood immunisation call-recall processes require cross-practice review.

Mental health physical checks trailed England despite +15.0% growth in statin therapy

Three-year progress lagged England most in mental health physical checks and heart failure review growth. For severe mental illness, BMI recording fell 1.9 pp (England +5.1 pp), and alcohol recording rose +2.0 pp (England +5.4 pp). Heart failure review growth was +0.8% (England +8.7%), though current review prevalence is 84.2% versus England's 78.5%. Conversely, clinical processes showed relative strength: QRISK ≥ 20% lipid therapy grew +15.0% (England +6.2%), COPD reviews rose +10.7% (England +2.8%), and blood pressure control under 80 rose +9.5% (England +3.2%).

What the data can't tell us: gaps and local assets

Options for the PCN

Each option in full

Provenance and audit trail

Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

Data sources

Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

Methods, data-quality notes and limitations